Everolimus-eluting xience V/promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus

JACC: Cardiovascular Interventions

Volumn 7, Issue 5, 2014, Pages 471-481

  Park, Kyung Woo ^a   Lee, Joo Myung ^a   Kang, Si Hyuck ^a   Ahn, Hyo Suk ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Rhew, Jay Young ^b   Hwang, Sun Ho ^c   Lee, Sung Yoon ^d   Kang, Tae Soo ^e   Kwak, Choong Hwan ^f   Hong, Bum Kee ^g   Yu, Cheol Woong ^h   Seong, In Whan ⁱ   Ahn, Taehoon ^j   Lee, Han Cheol ^k   Lim, Sang Wook ^l   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

^b Presbyterian Medical Center   (South Korea)

^c Gwangju Veterans Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Dankook University   (South Korea)

^f Gyeongsang National University   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Sejong General Hospital   (South Korea)

ⁱ Chungnam National University College of Medicine   (South Korea)

^j Gachon University   (South Korea)

^k Pusan National University School of Medicine   (South Korea)

^l CHA University   (South Korea)

more..

Author keywords

diabetes mellitus; drug eluting stent; everolimus; percutaneous coronary intervention; zotarolimus

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; INSULIN; ORAL ANTIDIABETIC AGENT; ZOTAROLIMUS; CARDIOVASCULAR AGENT; RAPAMYCIN;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; REVASCULARIZATION; SAFETY; STATISTICAL ANALYSIS; STENT THROMBOSIS; SUBDURAL HEMATOMA; TREATMENT OUTCOME; ZOTAROLIMUS ELUTING STENT; CARDIOVASCULAR MORTALITY; DIABETIC PATIENT; DRUG ELUTING CORONARY STENT; HEART MUSCLE REVASCULARIZATION; IN-STENT RESTENOSIS; ZOTAROLIMUS ELUTING RESOLUTE STENT; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CHI SQUARE DISTRIBUTION; COMPLICATION; DEVICES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; KAPLAN MEIER METHOD; MYOCARDIAL INFARCTION; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; PROSTHESIS; REGISTER; RISK FACTOR; SOUTH KOREA; STATISTICAL MODEL; TIME;

AGED; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; REGISTRIES; REPUBLIC OF KOREA; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901248019     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2013.12.201     Document Type: Article

References (23)

1. I. Moussa, M.B. Leon, and D.S. Baim et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy Circulation 109 2004 2273 2278
2. M. Sabaté, P. Jiménez-Quevedo, D.J. Angiolillo for the DIABETES Investigators Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) trial Circulation 112 2005 2175 2183
3. P. Ortolani, M. Balducelli, and P. Marzaroli et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry Circulation 117 2008 923 930
4. C. Stettler, S. Wandel, and S. Allemann et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948
5. S.J. Hong, M.H. Kim, and T.H. Ahn et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes Heart 92 2006 1119 1124
6. A. Kastrati, S. Massberg, and G. Ndrepepa Is diabetes the Achilles' heel of limus-eluting stents? Circulation 124 2011 869 872
7. W.J. Kim, S.W. Lee, S.W. Park for the ESSENCE-DIABETES Study Investigators Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial Circulation 124 2011 886 892
8. G.W. Stone, E. Kedhi, and D.J. Kereiakes et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
9. S. Silber, P.W. Serruys, and M.B. Leon et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the Resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program J Am Coll Cardiol Intv 6 2013 357 368
10. S. Silber, S. Windecker, P. Vranckx for the RESOLUTE All Comers Investigators Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247
11. K. Tandjung, H. Sen, and M.K. Lam et al. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting Resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial J Am Coll Cardiol 61 2013 2406 2416
12. K.W. Park, J.M. Lee, and S.H. Kang et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries J Am Coll Cardiol 61 2013 536 544
13. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
14. P. Vranckx, D.E. Cutlip, and R. Mehran et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies EuroIntervention 5 2010 871 874
15. P.W. Serruys, S. Silber, and S. Garg et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents N Engl J Med 363 2010 136 146
16. C. von Birgelen, M.W. Basalus, and K. Tandjung et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial J Am Coll Cardiol 59 2012 1350 1361
17. X.S. Gu, and P.R. Rosenbaum Comparison of multivariate matching methods: structures, distances, and algorithms J Comput Graphic Stat 2 1993 405 420
18. J. Cohen Statistical Power Analysis for the Behavioral Sciences. Rev. ed 1977 Lawrence Erlbaum Associates, Inc. Hillsdale, NJ
19. S.P. de Boer, M.J. Lenzen, and R.M. Oemrawsingh et al. Evaluating the "all-comers" design: a comparison of participants in two "all-comers" PCI trials with non-participants Eur Heart J 32 2011 2161 2167
20. A.J. Saltzman, G.W. Stone, and B.E. Claessen et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J Am Coll Cardiol Intv 4 2011 1011 1019
21. C. Wu, E.L. Hannan, G. Walford, and D.P. Faxon Utilization and outcomes of unprotected left main coronary artery stenting and coronary artery bypass graft surgery Ann Thorac Surg 86 2008 1153 1159
22. B. Brodie, Y. Pokharel, and A. Garg et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction J Am Coll Cardiol Intv 5 2012 1043 1051
23. J.K. Jensen, L.O. Jensen, and C.J. Terkelsen et al. Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry Catheter Cardiovasc Interv 81 2013 260 265